| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Are we ready for precision medicine for Autism? And who wants it?
|
Loth, Eva
|
|
|
48 |
C |
p. 32-33
|
artikel
|
| 2 |
Assessment of outcomes in autism clinical trials over the course of development
|
Dawson, Geraldine
|
|
|
48 |
C |
p. 40-41
|
artikel
|
| 3 |
A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders
|
Díaz-Caneja, CM
|
|
|
48 |
C |
p. 49-88
|
artikel
|
| 4 |
Comorbidities and behavioral issues
|
Bugarski-Kirola, Dragana
|
|
|
48 |
C |
p. 45-46
|
artikel
|
| 5 |
Contents
|
|
|
|
48 |
C |
p. CO4
|
artikel
|
| 6 |
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions
|
McCracken, James T.
|
|
|
48 |
C |
p. 3-31
|
artikel
|
| 7 |
Drug development in ASD, an ISCTM-ECNP joint adventure
|
Arango, Celso
|
|
|
48 |
C |
p. 1-2
|
artikel
|
| 8 |
ECNP Calendar of Meetings
|
|
|
|
48 |
C |
p. II
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
48 |
C |
p. IFC
|
artikel
|
| 10 |
Inclusion of individuals with low IQ in drug development for autism spectrum disorder
|
Farmer, Cristan
|
|
|
48 |
C |
p. 37-39
|
artikel
|
| 11 |
Refining biomarker evaluation in ASD
|
McPartland, James C.
|
|
|
48 |
C |
p. 34-36
|
artikel
|
| 12 |
Regulatory considerations in drug development for autism spectrum disorders
|
Mantua, Valentina
|
|
|
48 |
C |
p. 47-48
|
artikel
|
| 13 |
The role of digital medicine in autism spectrum disorder
|
Pandina, Gahan
|
|
|
48 |
C |
p. 42-44
|
artikel
|
| 14 |
Transcranial direct current stimulation in Autism Spectrum Disorder: A systematic review and meta-analysis
|
García-González, Sara
|
|
|
48 |
C |
p. 89-109
|
artikel
|
Tijdschrift beschrijving